Aranda, Richard

Becker, Jean-Claude

Berman, Alberto

Codding, Christine

Dougados, Maxime

Keiserman, Mauro

le Bars, Manuela

Nayiager, Sauithree

Nys, Marleen

Poncet, Coralie

Reed, Diane Moniz

Saldate, Cristina

Schiff, Michael

Songcharoen, Suthin

English

PubMed

M. Schiff

M. Keiserman

C. Codding

S. Songcharoen

A. Berman

S. Nayiager

C. Saldate

R. Aranda

J.-C. Becker

M. Nys

M. le Bars

D. M. Reed

C. Poncet

M. Dougados

Crossref

Annals of the Rheumatic Diseases

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of inﬂ iximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. Rheumatology

American College of Rheumatology. Preliminary deﬁ nition of improvement in rheumatoid arthritis. Arthritis Rheum

Assessment of patient satisfaction in activities of daily living using a modiﬁ ed Stanford Health Assessment Questionnaire. Arthritis Rheum

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum

Dose escalation of inﬂ iximab in clinical practice: improvements seen may be explained by a regression-like effect. Ann Rheum Dis

Efﬁ cacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis

Modiﬁ ed disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum

Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efﬁ cacy and safety at twenty-four weeks. Arthritis Rheum

Safety and efﬁ cacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study.

The 6-month safety and efﬁ cacy of abatacept in patients with rheumatoid arthritis who underwent a washout after antitumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis

The safety of inﬂ iximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum

Titration of inﬂ iximab treatment in rheumatoid arthritis patients based on response patterns. Rheumatology

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3184243

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

Abstract

Similar works

Full text

Available Versions

Crossref